fb image 1140 captis executive search management consulting leadership board services

Antengene announces China’s NMPA approval for IND application for ATG-019 clinical trial

fb image 1140 captis executive search management consulting leadership board services

Antengene has announced that China’s National Medical Products Administration (NMPA) has given approval to investigational new drug (IND) application for Phase I clinical trials of ATG-019 (monotherapy or combined with niacin ER) in patients with advanced solid tumors or non-Hodgkin’s lymphoma (NHL).

Antengene has announced that China’s National Medical Products Administration (NMPA) has given approval to investigational new drug (IND) application for Phase I clinical trials of ATG-019 (monotherapy or combined with niacin ER) in patients with advanced solid tumors or non-Hodgkin’s lymphoma (NHL).

Developed by Karyopharm Therapeutics, ATG-019 is a global first-in-class, oral of p21-activated kinase 4 (PAK4) and nicotinamide phosphoribosyltransferase (NAMPT).

Clinical-stage biopharmaceutical company Antengene signed an agreement with Karyopharm for the clinical development, manufacturing and commercialisation of ATG-019 in Greater China, Australia, New Zealand, South Korea, and the ASEAN countries.

The company has recently begun conducting a Phase I clinical trial to evaluate safety and tolerability of ATG-019 in advanced solid tumours and NHL in Taiwan.

It is also planning to conduct a combination study of ATG-019 and anti-PD-1 antibody to treat anti-PD-1 resistant patients.

Antengene founder, chairman and CEO Jay Mei said: “The NMPA‘s approval of the IND application for ATG-019 indicates the potential of this drug to be applied to Chinese patients. We look forward to initiating the first clinical trial of ATG-019 in mainland China.

“ATG-019 is an orally available dual PAK4/NAMPT inhibitor that achieves synergistic antitumor effects through the co-inhibition of the two pathways.

“We believe that ATG-019, as a novel agent under investigation, can potentially provide an additional treatment option for patients with advanced solid tumor and NHL.”

The company noted that the dual PAK4/NAMPT inhibitor can lead to antitumor effects through energy depletion, inhibition of DNA repair, cell cycle arrest, inhibition of proliferation, and cell apoptosis.

This is not a CAPTIS article. Originally, it was published here.